FAFrancesco Aragona

Francesco Aragona

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesco Aragona has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Accuracy of 3 Tesla pelvic phased-array multiparametric MRI in diagnosing prostate cancer at repeat biopsy

    by Pietro Pepe, Antonio Garufi, Giandomenico Priolo, Giuseppe Dibenedetto, Michele Salemi, Michele Pennisi, Filippo Fraggetta, Francesco Aragona, Michele Barbera

    Multiparametric pelvic magnetic resonance imaging (mpMRI) accuracy in prostate cancer (PCa) diagnosis was evaluated.


  • Open Access

    Primary carcinoid tumour of the testis: A case-report

    by Letterio D’arrigo, Angela Costa, Filippo Fraggetta, Antonio Cacciola, Astrid Bonaccorsi, Francesco Savoca, Francesco Aragona

    Testicular carcinoid tumours (TCT) account for less than 1% of all testicular neoplasms. A 17-year-old male underwent radical orchiectomy for a painful indurated and increased in size right testicle; a mixed echogenic mass, with a central homogeneous area surrounded by a hypoechoic edge with calcifications was found at ultreasound with increased vascularity at color Doppler examination. Biochemical markers were within normal limits. These symptoms are not specific and the majority of TCT are only diagnosed on histopathology. Patients should undergo long-term biochemical and radiological follow-up given potential for delayed metastases, in one case 17 years after primary treatment.


    • 1 February 2014
      • Vol. 34  (2) , 937-41

    PSA nadir and outcome in 100 patients with pT3b prostate cancer.

    by Pietro Pepe, Giuseppina Improta, Filippo Fraggetta, Carmela Emmanuele, Vittorio Simeon, Giuseppe Dibenedetto, Maurizio Colecchia, Francesco Aragona

    The prostate-specific antigen (PSA) nadir and long-term outcome in patients with pT3b prostate cancer were evaluated. From July 2000 to December 2012, in 100 patients (median age=62 years) with pT3b prostate cancer following radical retropubic prostatectomy (RRP) preoperative and pathological findings predictive of PSA nadir (≤0.2 vs. >0.2 ng/ml) were retrospectively evaluated; moreover, biochemical recurrence-free survival (bRFS), cancer specific survival (CSS) and overall survival (OS) in patients who underwent watchful waiting (16 cases), adjuvant (84 cases) and salvage (10 cases) therapy were recorded. A PSA nadir >0.2 ng/ml was correlated with node involvement, Gleason score ≥9, cT2, PSA >20 ng/ml, positive surgical margins and total cancer percentage >20%. At a median follow-up of 90 months (range=10-155 months) bRFS, OS and CSS were 92%, 96% and 80%, respectively. Radical retropubic prostatectomy combined with adjuvant and salvage treatments demonstrated a satisfactory outcome for pT3b prostate cancer.

  • Open Access

    Erectile function after repeat saturation prostate biopsy: Our experience in 100 patients

    by Pietro Pepe, Francesco Pietropaolo, Giuseppe Dibenedetto, Francesco Aragona

    Erectile dysfunction (ED) incidence following repeat saturation prostate biopsy (SPBx) was evaluated.


    • 1 March 2013
      • Vol. 33  (3) , 1195-9

    Prostate cancer detection at repeat biopsy: can pelvic phased-array multiparametric MRI replace saturation biopsy?

    by Pietro Pepe, Antonio Garufi, Giandomenico Priolo, Giuseppe Candiano, Francesco Pietropaolo, Michele Pennisi, Filippo Fraggetta, Francesco Aragona

    Magnetic resonance imaging (MRI) accuracy in prostate cancer (PCa) diagnosis in men submitted to saturation prostate biopsy (SPBx) was evaluated. From June 2011 to December 2012, 78 patients (median 63 years) underwent repeat SPBx (median 28 cores). Multiparametric MRI using a 3 Tesla pelvic phased-array coil was performed before SPBx and lesions suspicious for PCa were submitted to additional targeted biopsies. A T1c PCa was found in 32 (41%) cases. SPBx vs. MRI-suspicious targeted biopsy diagnosed 28 (87.5%) vs. 26 (81.2%) PCa missing four (12.5%) and six (18.8%) cancers localized in the anterior zone and in the lateral margin of the prostate, respectively; moreover, MRI diameter lesions correlated with PCa diagnosis and Gleason score (p10 mm resulted as highly predictive of cancer (about 70% of the cases).


    • 1 February 2013
      • Vol. 20  (1) , 6620-4

    Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.

    by Pietro Pepe, Francesco Aragona

    To evaluate Prostate Cancer Prevention Trial (PCPT) risk calculator versus prostate cancer gene 3 (PCA3) score versus case-finding protocol accuracy in prostate cancer diagnosis in patients with prostate-specific antigen (PSA) below 10 ng/mL submitted to repeat saturation biopsy (SPBx). From December 2010 to December 2011, 100 patients (median 66 years) underwent a SPBx (median 30 cores); the indications for repeat biopsy were those of a case-finding protocol: PSA values between 4.1 ng/mL-10 ng/mL or 2.6 ng/mL-4 ng/mL with F/T PSA ≤ 25% and ≤ 20%, respectively. All patients had negative digital rectal examination (DRE) and median PSA was 7.9 ng/mL. The performance of PCPT risk calculator (alone, combined with PSA free/total ( F/T) or PCA3 score) and PCA3 score in comparison with the case-finding protocol results (alone or combined with PCA3 score) was retrospectively evaluated in terms of detection rate for cancer and number of avoided biopsies. Prostate cancer was found in 28 (28%) patients; in the presence and absence of prostate cancer median PCA3 score was 57 versus 35 (p < 0.05). Using PCPT risk calculator (cut off probability of 25%) combined with PCA3 score no prostate cancer would be missed avoiding 8% of unnecessary biopsies. PCA3 score > 20 missed 7.2% of cancer; the case-finding protocol combined with PCA3 score > 35 would save 22% of avoidable biopsies, missing no cancer if all patients with PSA F/T ≤ 15% would undergo prostate biopsy irrespective of PCA3 values. PCA3 score improves PCPT risk calculator accuracy in prostate cancer diagnosis; moreover, PCA3 score combined with PSA F/T reduce number of unnecessary biopsies (about 20%).


    • 1 December 2012
      • Vol. 84  (4) , 208-10

    Solitary lung metastasis after radical prostatectomy in presence of undetectable PSA.

    by Pietro Pepe, Filippo Fraggetta, Francesco Tornabene, Maurizio Nicolosi, Francesco Aragona

    Clinical recurrence in the absence of biochemical PSA failure is uncommon and accounts for less than 1%; we report a rare case of solitary lung metastasis in a patient with undetectable PSA level (<0.1 ng/mL) after radical prostatectomy (RP) for prostate cancer (PCa). An asymptomatic 75-year-old man nine years after RP showed a solitary lung mass (about 2 cm) at chest radiography; the 18-FDG-PET/CT confirmed the presence of an isolated mass suspicious for primitive pulmonary cancer. The initial histological specimen after RP showed a mixed acinar and ductal PCa (Gleason score 7, pT3aNO stage, negative surgical margins). A segmental pulmonary resection was performed and definitive specimen demonstrated a single ductal PCa metastasis; after six months from surgery the patient was free from recurrence. In conclusion, in patients with atypical PCa variants imaging studies may be considered in the follow up even in presence of undetectable PSA because they could benefit from early salvage therapy.


    • 1 December 2012
      • Vol. 84  (4) , 227-9

    PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients.

    by Michele Barbera, Pietro Pepe, Quintino Paola, Francesco Aragona

    To evaluate PCA3 score accuracy in prostate cancer (PCa) diagnosis in patients undergoing repeat saturation prostate biopsy (SPBx). From January 2010 to March 2012, 177 patients (median 64 years) with primary negative extended biopsy underwent a SPBx (median 28 cores) for persistent suspicion of PCa. The indications for repeat biopsy were: PSA > 10 ng/mL, PSA values between 4.1-10 or 2.6-4 ng/mL with free/total PSA < 25% and < 20%, respectively; moreover, before performing SPBx PCA3 score was evaluated. Median PSA was 9.5 ng/mL (range: 3.7-28 ng/mL): in 74 (41.8%) cases PSA was > 10 ng/mL, in 99 (56%) and 4 (2.2%) was included between 4-10 and 2.6-4 ng/mL, respectively. Median PCA3 score was equal to 52 (range 3-273); 140 (79%) and 100 (56.5%) patients had a PCA3 score greater than 20 and 35, respectively. A T1c PCa was found in 48 patients (27.1%); PCA3 score was 60 (median; range: 7-208) in the presence of PCa and 34 (median; range: 3-268) in the absence of cancer (p < 0.05). Diagnostic accuracy, sensitivity, specificity, PPV and NPV of PCA3 score cut-off of 20 vs. 35 in PCa diagnosis were 43.5 vs. 50.2%, 91.7 vs. 73%, 25.6 vs. 41.8%, 31.5 vs. 35% and 89.5 vs. 80.6%, respectively. PCA3 score reduce number of unnecessary repeat SPBx; using a PCA3 cut-off of 20 vs 35 would have avoided 21% vs. 37.8% of biopsies while missing 8.4% (4 cases) vs. 27% (13 cases) of significant PCa, respectively.


    • 1 June 2012
      • Vol. 84  (2) , 101-3

    Partial priapism secondary to idiophatic segmental thrombosis of corpora cavernosa.

    by Pietro Pepe, Paolo Panella, Giuseppe Candiano, Antonio Garufi, Giandomenico Priolo, Francesco Aragona

    A 51-year-old man presented at our department 2 days after the onset of a painful mass in the perineum and dysuria. Diagnosis of partial priapism secondary to proximal segmental corpora cavernosa thrombosis was made through colordoppler ultrasound (CDU) and magnetic resonance imaging (MRI). Treatment consisted of administration of systemic anticoagulation drugs (acenocumarol) and local injection of ethylephrine chloridrate. The thrombosis resolved after two months with incomplete restoration of erectile function (loss of rigidity). In conclusion, on the basis of previous reports (23 cases reported in literature) and our experience, in presence of painful mass in the perineum, CDU and MRI evaluation allows to make diagnosis of the rare proximal partial priapism that as first option should be treated conservatively.


    • 1 March 2012
      • Vol. 84  (1) , 32-5

    Does Ki-67 staining improve quantitative histology in preoperative prostate cancer staging?

    by Pietro Pepe, Filippo Fraggetta, Giuseppe Candiano, Francesco Aragona

    To evaluate accuracy of Ki-67 expression on biopsy specimens in comparison with quantitative histology findings for preoperative prostate cancer (PCa) staging. From January 2008 to January 2010, 126 patients (median age 63 years) underwent radical retropubic prostatectomy; median PSA was 9.1 ng/mL; 98 and 28 patients had a clinical stage T1c and T2, respectively. The following variables of quantitative histology were evaluated as predictive of non organ-confined (OC) PCa: Gleason score > 6, TPC > 20%, GPC > 50%, cancer-positive cores > 2, presence of cancer-positive cores in both lateral margins and bilateral PCa. Value of Ki-67% staining in all cancerous cores was calculated. Sixty (47.7%) patients had a non OC-PCa with positive nodes in 12 (20%) cases. The mean Ki-67 score was 4.4%: 3.7% in OC-PCa and 5.6% in non-OC-PCa, respectively. Predictive positive value (PPV) of quantitative histology, Ki-67 (cut-off > 5%) and both parameters to predict a non-OC-PCa vs an OC-PCa was equal to 90%, 40% and 93.4%, vs 36.6%, 78.8% and 78.8%, respectively. Ki-67 staining on biopsy specimens does not improve quantitative histology in predicting non-OC-PCa; moreover, the low expression of Ki-67, even in presence of advanced disease, decreases its prognostic value in predicting an OC-PCa.